Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Si Zhang

Pain Medicine Stamford, CT Doctor of Osteopathy

NPI 1306282652 CMS profile 1391412

29 Hospital Plz Ste 602, Stamford, CT 06902

Open in the dashboard

General payments

$1,239

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Si Zhang of Stamford, CT is reported in the CMS Open Payments database as having received $1,239 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 1
2024 General $75 2
2023 General $364 3
2021 General $194 2
2020 General $117 3
2019 General $454 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Si Zhang
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Si Zhang were reported at $34. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Si Zhang Pain Medicine median Middle half National median
2019 $454 $498 $126–$1,682 $163
2020 $117 $284 $80–$910 $114
2021 $194 $399 $112–$1,219 $132
2022 $0 $455 $137–$1,484 $149
2023 $364 $484 $128–$1,495 $160
2024 $75 $498 $131–$1,540 $164
2025 $34 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $211 4 payments
  2. Abbott Laboratories $166 2 payments
  3. Inari Medical, Inc. $155 1 payment
  4. Saluda Medical Americas, Inc. $151 1 payment
  5. Flowonix Medical Incorporated $110 1 payment
  6. Bioness Inc $110 1 payment
  7. Becton, Dickinson and Company $109 3 payments
  8. AbbVie, Inc. $100 1 payment
  9. Relievant Medsystems, Inc. $61 1 payment
  10. Nevro Corp. $59 1 payment
  11. Other $7 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,020 13 payments
  2. Entertainment $110 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $109 3 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $166 2 payments
  2. FLOWTRIEVER CATHETER, S $155 1 payment
  3. CT THROMBECTOMY SYSTEM KIT $155 1 payment
  4. Evoke SCS $151 1 payment
  5. GENERAL - PAIN MANAGEMENT $117 3 payments
  6. Prometra II $110 1 payment
  7. Stimrouter for Pain $110 1 payment
  8. UBRELVY $100 1 payment
  9. GENERAL PAIN MANAGEMENT $94 1 payment
  10. Intracept $61 1 payment
  11. Other $100 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,330

Median for Pain Management: 951

Drug cost

$141,767

Median for Pain Management: $26,034

Branded share of claims

23.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 55 $44,346
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 92 $13,817
Lyrica Pregabalin Brand 15 $13,680
Oxycontin Oxycodone Hcl Brand 13 $9,736
Ztlido Lidocaine Brand 16 $9,654
Pregabalin Generic 262 $8,128
Buprenorphine Generic 34 $5,770
Gabapentin Generic 361 $5,219
Movantik Naloxegol Oxalate Brand 13 $5,186
Lidocaine Generic 42 $4,987

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$112,225

Of which drugs: $37

Medicare patients

321

Average age 75

Services billed

1,375

206 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 39%
Ischemic heart disease 38%
Diabetes 32%
Heart failure 27%
Atrial fibrillation 25%
Osteoporosis 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 28 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record